Related references
Note: Only part of the references are listed.Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer
Eunice L. Kwak et al.
CANCER DISCOVERY (2015)
Combined Targeting of PDK1 and EGFR Triggers Regression of Glioblastoma by Reversing the Warburg Effect
Kiran Kumar Velpula et al.
CANCER RESEARCH (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations
C. M. Furcht et al.
ONCOGENE (2013)
Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer
Antonija Kreso et al.
SCIENCE (2013)
Cell-to-Cell Variability Analysis Dissects the Plasticity of Signaling of Common γ Chain Cytokines in T Cells
Jesse W. Cotari et al.
SCIENCE SIGNALING (2013)
Receptor Tyrosine Kinase Genes Amplified in Glioblastoma Exhibit a Mutual Exclusivity in Variable Proportions Reflective of Individual Tumor Heterogeneity
Suzanne E. Little et al.
CANCER RESEARCH (2012)
Antitumor Activity of NVP-BKM120-A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells
Dimpy Koul et al.
CLINICAL CANCER RESEARCH (2012)
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
Eudocia Q. Lee et al.
NEURO-ONCOLOGY (2012)
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response
Nicholas J. Szerlip et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Differential Sensitivity of Glioma-versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors
Igor Vivanco et al.
CANCER DISCOVERY (2012)
Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
Matija Snuderl et al.
CANCER CELL (2011)
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans
Kun-Wei Liu et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Coactivated Platelet-Derived Growth Factor Receptor α and Epidermal Growth Factor Receptor Are Potential Therapeutic Targets in Intimal Sarcoma
Barbara Dewaele et al.
CANCER RESEARCH (2010)
Epidermal Growth Factor Receptor Expression Identifies Functionally and Molecularly Distinct Tumor-Initiating Cells in Human Glioblastoma Multiforme and Is Required for Gliomagenesis
Stefania Mazzoleni et al.
CANCER RESEARCH (2010)
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas
Tatsuya Ozawa et al.
GENES & DEVELOPMENT (2010)
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
Maria-del-Mar Inda et al.
GENES & DEVELOPMENT (2010)
Tyrosine phosphatases Shp1 and Shp2 have unique and opposing roles in oligodendrocyte development
Emory Kuo et al.
JOURNAL OF NEUROCHEMISTRY (2010)
Different Response of Human Glioma Tumor-initiating Cells to Epidermal Growth Factor Receptor Kinase Inhibitors
Fabrizio Griffero et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations
Cameron Brennan et al.
PLOS ONE (2009)
Use of proximity ligation to screen for inhibitors of interactions between vascular endothelial growth factor A and its receptors
Sigrun M. Gustafsdottir et al.
CLINICAL CHEMISTRY (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Binomial Mitotic Segregation of MYCN-Carrying Double Minutes in Neuroblastoma Illustrates the Role of Randomness in Oncogene Amplification
Gisela Lundberg et al.
PLOS ONE (2008)
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Jayne M. Stommel et al.
SCIENCE (2007)
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma
Paul H. Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Heterodimerization of FGF-receptor 1 and PDGF-receptor-α:: a novel mechanism underlying the inhibitory effect of PDGF-BB on FGF-2 in human cells
D Faraone et al.
BLOOD (2006)
STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma
L Geng et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation
I Kratchmarova et al.
SCIENCE (2005)
A novel role for Gab1 and SHP2 in epidermal growth factor-induced ras activation
A Montagner et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors
T Araki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Receptor heterodimerization: Essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation
Y Saito et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
A critical pole for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of Ras and mitogen-activated protein kinases by epidermal growth factor
A Yart et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity
ZQ Shi et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)